As the global pharmaceutical industry races to capitalize on the lucrative weight-loss market, China’s Hansoh Pharmaceutical has reached a pivotal moment in the development of its home-grown metabolic treatment. In June 2026, the company announced that its New Drug Application (NDA) for Olapepeptide, a novel dual-target weight-loss drug, was officially accepted by China’s National Medical Products Administration (NMPA). This milestone marks the transition of a domestic innovation into a serious contender on the international stage.
Obesity has evolved into a staggering public health crisis in China, with more than 50% of adults now classified as overweight or obese. While the current generation of GLP-1 receptor agonists has revolutionized treatment, many patients struggle to maintain long-term adherence due to debilitating gastrointestinal side effects. Olapepeptide, a GLP-1/GIP dual-receptor agonist, seeks to address this gap by prioritizing patient tolerability alongside significant weight reduction.
Data from a Phase III clinical trial released in March highlights the drug’s potential as a top-tier therapeutic. Over a 48-week period, participants achieved a maximum average weight loss of 19.3%, with over 97% of subjects reaching the clinically significant 5% reduction threshold. These figures place Olapepeptide in the same league as global blockbusters like Eli Lilly’s Tirzepatide, yet it is the safety profile that has truly captured the attention of the scientific community.
The drug employs a unique 'bi-biased' molecular design that selectively activates metabolic pathways while avoiding the signaling routes responsible for nausea and vomiting. Clinical results showed nausea rates below 10% and vomiting rates below 5%, figures substantially lower than those typically associated with established GLP-1 treatments. By optimizing this balance between potency and comfort, Hansoh is positioning its candidate not just as an alternative, but as a potential refinement of the dual-agonist class.
International validation arrived in mid-June when Olapepeptide’s pharmacological data was showcased at the ENDO 2026 conference in the United States. This presentation at one of the world's premier endocrinology forums signals that Chinese pharmaceutical firms are no longer content with merely following Western trends. Instead, they are increasingly presenting original research that challenges the current standards of metabolic care on a global scale.